

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number 09/382,837

Filing Date 08/25/99

First Named Inventor Gary Borodic

Group Art Unit 1614 1644

Examiner Name EWALDT

Attorney Docket Number BORO-101

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ABE		MERAYO-LLOVES J, CALONGE M, FOSTER CS Experimental model of allergic conjunctivitis to ragweed in guinea pig Curr. Eye Research 14:487-494, 1995.	
		JANKOVIC J, BRIN M Therapeutic uses of botulinum toxin 1991, NEJM 324:1186-1194.	
		BUSHARA KO, PARKODM Botulinum toxin and sweating J Neurol, Neurosurg., Pyschtr. 1994: 57(11), 1437-1438.	
		PARRICHA PJ, RAVICH WJ, HENDRIX TR, SOSTRE S, JONES B, KALLO AN Intrasphincteric Botulinum toxin for the treatment of achalasia NEJM 1995: 332,774-778	
ABE		BOTTINGER H, REUNER KH, AKTORIES K Inhibition of histamine release from rat mast cells by botulinum C2 toxin. Int Arch Allergy Appl Immunol 84:380-384, 1987	

Examiner
Signature

Ewaldt

Date

Considered

6/7/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
33677-00000

SERIAL NO.:
09/382,837

APPLICANT:
Gary BORODIC

FILING DATE:
August 25, 1999

GROUP ART UNIT:
1644

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>hfe</i>	/	6,113,915	09/05/00	Aoki et al.			
	/	6,063,768	05/16/00	First			
	/	5,837,265	11/17/98	Montal et al.			
	/	5,714,468	02/03/98	Binder			
	/	5,696,077	12/09/97	Johnson et al.			
	/	5,674,205	10/07/97	Pasricha et al.			
	/	5,670,484	09/23/97	Binder			
	/	5,562,907	10/08/96	Arnon			
	/	5,401,243	03/28/95	Borodic			
	/	5,298,019	03/29/94	Borodic			
	/	5,183,462	02/02/93	Borodic			
	/	5,053,005	10/01/91	Borodic			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>hfe</i>	/	WO 95/28171	10/26/95	PCT				

#9

RECEIVED



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
33677-00000SERIAL NO.:
09/382,837

INFORMATION DISCLOSURE STATEMENT

APPLICANT:
Gary BORODICFILING DATE:
August 25, 1999GROUP ART UNIT:
1644

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

18	/	Acquadro, M., et al., Treatment of myofascial pain with botulinum A toxin, <i>Anesthesiology</i> 3/94; 80(3):705-6.
19	/	Amann, R., et al., Intraplantar injection of nerve growth factor into the rat hind paw: local edema and effects on the thermal nociceptive threshold, <i>Pain</i> 1995; 64:323-329.
20	/	Ashikaga, T., et al., Multiple daily insulin injections in the treatment of diabetic retinopathy, <i>The Job Study Revisited, Diabetes</i> 5/78; 27(5):592-6.
21	/	Bischoff, S.C., et al., Effect of Nerve Growth Factor on the Release of Inflammatory Mediators by Mature Human Basophils, <i>Blood</i> 5/15/92; 79(10):2663-2669.
22	/	Borodic, G., Myasthenic crisis after botulinum toxin. <i>Lancet</i> 12/5/98; 352(9143):1832.
23	/	Borodic, G, et al., Botulinum toxin therapy, immunologic resistance, and problems with available materials, <i>Neurology</i> 1/96; 46(1):26-9.
24	/	Borodic, G., et al., Antibodies to botulinum toxin, <i>Neurology</i> 1/95; 45(1):204.
25	/	Borodic, G., Therapeutic botulinum toxin, <i>Lancet</i> 11/12/94; 344(8933):1370.
26	/	Borodic, G., et al., New concepts in botulinum toxin therapy, <i>Drug Saf</i> 9/94; 11(3):145-52.
27	/	Borodic, G., et al., Antibodies to Botulinum toxin, <i>Ophthalmology</i> 7/94; 11(3):1158-9.
28	/	Borodic, G., et al., Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections, <i>Movement Disorders</i> 1994; 9(1):31-9
29	/	Borodic, G., et al., Botulinum A toxin for treatment of strabismic amblyopia, <i>Arch Ophthalmol</i> 1993; 111(10):1412-5.
30	/	Borodic, G., et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study, <i>Ophthal Plast Reconstr Surg</i> 1993; 9(3):182-90.
31	/	Borodic, G., et al. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry, <i>Plast Reconstr Surg</i> 12/92; 90(6):972-7.
32	/	Borodic, G., et al. Effects of repeated botulinum toxin injections on orbicularis oculi muscle, <i>J Clin Neuroophthalmol</i> 6/92; 12(2):121-7.
33	/	Borodic, G., et al. Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle, <i>Head Neck</i> 1-2/92; 14(1):33-7.
34	/	Borodic, G., et al. Treatment of spasticity with botulinum toxin, <i>Ann Neurol</i> 1/92; 31(1):113.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
33677-00000

SERIAL NO.:
09/382,837

INFORMATION DISCLOSURE STATEMENT

APPLICANT:
Gary BORODIC

FILING DATE:
August 25, 1999

GROUP ART UNIT:
1644

(Use several sheets if necessary)


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

1	✓	Borodic, G., Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling, <i>Ophthal Plast Reconstr Surg</i> 1992; 8(2):137-42.
2	✓	Borodic, G., et al. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis, <i>Plast Reconstr Surg</i> 2/91; 87(2):285-9.
3	✓	Borodic, G., et al. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy, <i>Ophthal Plast Reconstr Surg</i> 1991; 7(1): 54-60.
4	✓	Borodic, G., et al. Botulinum A toxin for the treatment of spasmodic torticollis dysphagia and regional toxin spread, <i>Head Neck</i> 9-10/90; 12(5):392-9.
5	✓	Borodic, G., et al. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin, <i>Plast Reconstr Surg</i> 3/89; 83(3):546-54.
6	✓	Borodic, G., et al. Dermis fat graft in eviscerated sockets, <i>Ophthal Plast Reconstr Surg</i> 1989; 5(2):144-9.
7	✓	Borodic, G., et al. Immunoglobulin deposition in localized conjunctival amyloidosis, <i>Am J Ophthalmol</i> 11/84; 98(5):617-22.
8	✓	Borodic, G., et al. Botulinum A toxin for the treatment of blepharospasm and strabismus. <i>Plast Reconstr Surg</i> 1991; 87(2):285-9.
9	✓	Borodic, G., et al. Photophobia and benign essential blepharospasm.
10	✓	Borodic, G., et al. Therapeutic botulinum toxin: histologic effects and diffusion properties, <i>DasGupta BR, ed, Botulinum and Tetanus Neurotoxins. Plenum Press, New York</i> 1993, 623-45.
11	✓	Borodic, G., Botulinum toxin: issues and applications, <i>Otolaryngology Head Neck Surg</i> 1999; 7:219-25. <i>Current Opinion in</i>
12	✓	Borodic, G., et al. Botulinum toxin: histology of the eye. <i>SOURCE?</i>
13	✓	Bottinger, H., et al., Inhibition of histamine release from rat mast cells by botulinum C2 toxin, <i>Int Arch Allergy Appl Immunol</i> 1987; 84(4):380-4.
14	✓	Brooks, A., et al., Reactive oxygen species generation and histamine release by activated mast cells: modulation by nitric oxide synthase inhibition, <i>Br J Pharmacol</i> 1999; 128:585-90.
15	✓	Calderone, J., et al., Intraocular pathology of trisomy 18 (Edwards's syndrome): report if a case and review of the literature, <i>Br J Ophthalmol</i> 3/83; 67(3):162-9.
16	✓	Chen, X., et al., NOS Inhibitor antagonism of PGE ₂ -induced mechanical sensitization of cutaneous C-fiber nociceptors in the rat, <i>Am Psych Soc</i> 1999; 963-6.
17	✓	Dines, K., et al., Mast cell interactions with the nervous system: relationship to mechanisms of disease, <i>J Neuropathol Exp Neurol</i> 1997, 56(6):627-40.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.: 33677-00000 APPLICANT: Gary BORODIC FILING DATE: August 25, 1999	SERIAL NO.: 09/382,837 GROUP ART UNIT: 1644
--	---	--

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

182	35	/	Fujishima, H., et al., Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis, <i>Clin Exp Allergy</i> 1997; 27:372-8.
	36	/	First, E., et al., Dose standardization of botulinum toxin, <i>Lancet</i> 4/23/94; 343(8904):1035.
	37	/	Hayashi, N., et al., Giant cell angiofibroma of the orbit and eyelid, <i>Ophthalmology</i> 6/99; 106(6):1223-9.
	38	/	Jensen, W., et al., The susceptibility of the mallard duck (<i>Anas platyrhynchos</i>) to <i>Clostridium botulinum</i> C2 toxin, <i>Jpn J Med Sci Biol</i> 3/80; 33(2):81-6.
	39	/	Just, I., et al., ADP-ribosylation of <i>Drosophila</i> indirect-flight-muscle actin and arthrin by <i>Clostridium botulinum</i> C2 toxin and <i>Clostridium perfringens</i> iota toxin, <i>Biochem J</i> 4/93; 291 (Pt 2):409-12.
	40	/	Kinde, H., et al., <i>Clostridium botulinum</i> type-C intoxication associated with consumption of processed alfalfa hay cubes in horses, <i>J Am Vet Med Assoc</i> 9/15/91; 199(6):742-6.
	41	/	Lambiase, A., et al., Increase plasma levels of substance P in vernal keratoconjunctivitis, <i>Invest Ophthalmol Vis Sci</i> 9/97; 30(10):2161-4.
	42	/	Lambiase, A., et al., Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases, <i>IOVS</i> 6/98; 38(7):1272-5.
	43	/	Leon, A., et al., Mast cells synthesize, store, and release nerve growth factor, <i>Proc Natl Acad Sci</i> 4/94; 91 3739-43.
	44	/	Levi-Montalcini, R., et al., Update of the NGF saga, <i>J Neurol Sci</i> 1995; 130:119-127.
	45	/	Levi-Montalcini, R., et al., Nerve growth factor: from neurotrophin to neurokinin, <i>TINS</i> 1996; 19(11):514-20.
	46	/	Lewin, G., et al., Nerve Growth Factor and nociception, <i>TINS</i> 1993; 16(9):353-9.
	47	/	Matter, K., et al., Actin involvement in exocytosis from PC12 cells: studies on the influence of botulinum C2 toxin on stimulated noradrenaline release, <i>J Neurochem</i> , 2/89; 52(2):370-6.
	48	/	Mauss, S., et al., Inhibition of the contraction of the isolated longitudinal muscle of the guinea-pig ileum by botulinum C2 toxin: evidence for a role of G/F-actin transition in smooth muscle contraction, <i>Naunyn Schmiedebergs Arch Pharmacol</i> 9/89; 340(3):345-51.
	49	/	Mendell, L., et al., Neurotrophins, nociceptors, and pain, <i>Microscopy Res Technique</i> 1999; 45:252-61.
182	50	/	Nakamura, S., et al., C2 toxin production by <i>Clostridium botulinum</i> type C strains producing no C1 toxin, <i>Jpn J Med Sci Biol</i> 4/79; 32(2):128-9.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 33677-00000	SERIAL NO.: 09/382,837
 <p>INFORMATION DISCLOSURE STATEMENT</p> <p>(Use several sheets if necessary)</p>		APPLICANT: Gary BORODIC	
		FILING DATE: August 25, 1999	GROUP ART UNIT: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)			
182	51	✓	Nakamura, S., et al., Sporulation and C2 toxin production by Clostridium botulinum type C strains producing no C1 toxin, <i>Microbial Immunol</i> 1978; 22(10):591-6.
	52	✓	Ohishi, I., et al., Histopathological effect of botulinum C2 toxin on mouse intestines, <i>Infect Immun</i> 1/84; 43(1): 54-8.
	53		Ritter, A., et al., Effects of botulinum toxin on the ocular adnexa following definitive radiation therapy for sebaceous carcinoma of the ocular adnexa, <i>J Natl Cancer Inst Biol Phys</i> 3/15/96; 34(5):1189-90.
	54	✓	Pearce, L., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, <i>Toxicon</i> 9/97; 35(9):1373-412.
	55	✓	Pearce, L., et al., Botulinum toxin: death versus localized denervation, <i>J R Soc Med</i> 4/95; 88(4):239-40.
	56	✓	Pearce, L., et al., The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin, <i>Toxicon</i> 2/95; 33(2):217-27.
	57	✓	Pearce, L., et al., Measurement of botulinum toxin activity: evaluation of the lethality assay, <i>Toxicol Appl Pharmacol</i> 9/94; 128(1):69-77.
	58	✓	Pearce, L., et al., Botulinum toxin potency: a mystery resolved by the median paralysis, <i>J R Soc Med</i> 9/94; 87(9):571-2.
	59	✓	Ritter, A., et al., Regulation of myelinated nociceptor function by nerve growth factor in neonatal and adult rats, <i>Br Res Bul</i> 1993; 30:245-49.
	60	✓	Sanico, A., et al., Nerve growth factor expression and release in allergic inflammatory disease of the upper airways, <i>Am J Respir Crit Care Med</i> 2000; 161:1631-5.
	61	✓	Simpson, L., A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins, <i>J Pharmacol Exp Ther</i> 12/82; 223(3):695-701.
	62	✓	Simpson, L., Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin, <i>J Pharmacol Exp Ther</i> 9/84; 230(3):665-9.
	63		Tarsy, D., et al., Myasthenia gravis after botulinum toxin A for Meige syndrome, <i>Mov Disord</i> 7/00; 15(4):736-8.
	64	✓	Troll, G., et al., Diplopia after cataract surgery using 4% lidocaine in the absence of Wundtase, <i>J Clin Anesth</i> 11/99; 11(7):615-6.
	65		Wex, C., et al., Effects of clostridial botulinum C2 toxin and depolymerisation of actin on degranulation of eosinophils and mast cells, <i>Neuropharmacology Arch Pharmac</i> 1997; 355:319-27.
182	66	✓	Woelf, C., et al., Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation, <i>J Neurosci</i> 4/15/96; 16(8): 2716-23.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
33677-00000SERIAL NO.:
09/382,837

INFORMATION DISCLOSURE STATEMENT


APPLICANT:
Gary BORODICFILING DATE:
August 25, 1999GROUP ART UNIT:
1644

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

67	1	Yamaji, M., et al., Role of substance P in experimental allergic conjunctivitis in guinea pigs, <i>Meth Find Exp Clin Pharmacol</i> 1997; 19(9):637-43.
68	1	Buzzi, M.G., et al., Neurogenic model of migraine, <i>Cephalalgia</i> 1995; 15(4):277-80.
69	1	Moskowitz, M.A., et al., Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions, <i>J Neurol</i> 1991; 238 Suppl 1:S18-22.
70	1	Soter, N.A., et al., Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria, <i>N Engl J Med</i> 1980 Mar 13; 302(11):604-8.
71	1	Levine, J.D., et al., Intraneuronal substance P contributes to the severity of experimental arthritis, <i>Science</i> 1984 No 2; 226(4674):547-9.
72	1	Lassen, L.H., et al., Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine, <i>Neuroreport</i> 1995 Jul 31; 6(11):1475-9.
73	1	Buzzi, M.G., et al., 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation, <i>Brain Res</i> 1992 Jun 26; 583(1-2):137-49.
74	1	Dimitriadou, V., et al., Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation, <i>Neuroscience</i> 1992; 48(1):187-203.
75	1	Dimitriadou, V., et al., Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells, <i>Neuroscience</i> 1991; 44(1):97-112.
76	1	Kokumai, S., et al., Effect of capsaicin as a neuropeptide-releasing substance on sneezing reflex in a type I allergic animal model, <i>Int Arch Allergy Immunol</i> 1992; 98(3):256-61.
77	1	Takeda, N., et al., Neurogenic inflammation in nasal allergy: histochemical and pharmacological studies in guinea pigs. A review, <i>Acta Otolaryngol Suppl</i> 1993; 501:21-4.
78	1	Kellogg, D.L., et al., Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission, <i>Circ Res</i> 1995 Dec; 77(6):1222-8.
79	1	Meijer, F., et al., Nitric oxide plays a role as mediator of conjunctival edema in experimental allergic conjunctivitis, <i>Exp Eye Res</i> 1996 Apr; 62(4):359-65.
80	1	Wang, Z.Y., et al., The contribution of nitric oxide to endotoxin-induced ocular inflammation: interaction with sensory nerve fibres, <i>Br J Pharmacol</i> 1996 July; 118(6):1537-43.
81	1	T... and Dysfunction The Trigger Point Manual The ... and Principles, Chapter 2, pp. 29-33. Vlc-F

RECEIVED

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 33677-00000	SERIAL NO.: 09/382,837	TECH CENTER 1600/2900 MAY 21 2001
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT: Gary BORODIC		
				FILING DATE: August 25, 1999	GROUP ART UNIT: 1644	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)						
82	1	Headache after acoustic neuroma Journal of Otolaryngology, November 1994, Vol. 103, No. 6, pp. 793-797				
83	1	Benign essential blepharospasm 35 SOURCE				
EXAMINER		DATE CONSIDERED				
Ewdt		6/7/01				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.						